24 Recruiting Studies Using Iberdomide
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Iberdomide
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
📍 Rocky Mountain Cancer Centers — Aurora, Colorado
Multiple Myeloma
View Study & Checklist ➔Iberdomide Maintenance Therapy in Patients With Multiple Myeloma
📍 University of Nebraska Medical Center — Omaha, Nebraska
Multiple Myeloma
View Study & Checklist ➔A Study of Iberdomide (CC-220) in Combination With Elotuzumab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
📍 Icahn School of Medicine — New York, New York
Multiple Myeloma
View Study & Checklist ➔Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)
📍 Memorial Sloan Kettering Basking Ridge (Consent and Followup) — Basking Ridge, New Jersey
Multiple Myeloma
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
📍 UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program — San Francisco, California
Non-Hodgkin Lymphoma
View Study & Checklist ➔Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Plasma Cell Myeloma
View Study & Checklist ➔Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
📍 Local Institution - 035 — Hot Springs, Arkansas
Multiple Myeloma
View Study & Checklist ➔Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Multiple Myeloma
View Study & Checklist ➔Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
📍 Icahn School of Medicine at Mount Sinai — New York, New York
Multiple Myeloma
View Study & Checklist ➔Phase 1b/2: Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma
📍 Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
Newly Diagnosed Multiple Myeloma
View Study & Checklist ➔A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
📍 City of Hope National Medical Center /ID# 273132 — Duarte, California
Multiple Myeloma
View Study & Checklist ➔Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Recurrent Multiple Myeloma
View Study & Checklist ➔Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
📍 Mary Greeley Medical Center — Ames, Iowa
Recurrent Multiple Myeloma
View Study & Checklist ➔A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
Multiple Myeloma
View Study & Checklist ➔Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Beverly Hills Cancer Center /ID# 266921 — Beverly Hills, California
Multiple Myeloma
View Study & Checklist ➔Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Recurrent Multiple Myeloma
View Study & Checklist ➔Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
📍 Cross Cancer Institute — Edmonton, Alberta
Multiple Myeloma
View Study & Checklist ➔A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
📍 Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center — Coral Gables, Florida
Multiple Myeloma
View Study & Checklist ➔Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma
📍 University of Miami — Miami, Florida
Refractory Multiple Myeloma
View Study & Checklist ➔Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
📍 University of Calfornia, San Francisco — San Francisco, California
Multiple Myeloma
View Study & Checklist ➔Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
📍 Brigham and Women's Hospital — Boston, Massachusetts
Myeloma
View Study & Checklist ➔Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma
📍 Karmanos Cancer Institute — Detroit, Michigan
Multiple Myeloma
View Study & Checklist ➔Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Smoldering Plasma Cell Myeloma
View Study & Checklist ➔